
MannKind (MNKD) Stock Forecast & Price Target
MannKind (MNKD) Analyst Ratings
Bulls say
MannKind Corp's positive outlook is supported by potential label expansion for its Tyvaso DPI product, which could create new market opportunities and drive revenue growth. The possibility of a broader label, regardless of limitations, is viewed as a significant catalyst for MNKD's stock, particularly due to the ongoing interest in sub-group analyses involving patients with Pulmonary Arterial Hypertension (PAH). Additionally, historical correlations suggest that favorable developments for UTHR, related to Tyvaso, may also positively influence MannKind's stock performance.
Bears say
MannKind Corp's financial outlook is characterized by cautious estimates for its Afrezza product, projecting sales of $127 million by 2030, which may still be considered conservative depending on the success of pediatric market opportunities. Additionally, the valuation of its pipeline products, MNKD-101 and MNKD-201, incorporates low probabilities of success—40% for MNKD-101 and 30% for MNKD-201—indicating significant uncertainty regarding future revenue streams. Collectively, these factors contribute to a negative sentiment regarding the financial stability and growth potential of MannKind Corp.
This aggregate rating is based on analysts' research of MannKind and is not a guaranteed prediction by Public.com or investment advice.
MannKind (MNKD) Analyst Forecast & Price Prediction
Start investing in MannKind (MNKD)
Order type
Buy in
Order amount
Est. shares
0 shares